Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine for Pediatric Forearm Fracture Sedation
NCT03466242Phase 1Withdrawn
- Sponsor
- Phoenix Children's
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexmedetomidine in distal radius fracture (2 arms), sponsored by Phoenix Children's. Primary endpoints: Sedative effects of intranasal Dexmedetomidine at 12 months and Analgesic effects of intranasal Dexmedetomidine at 12 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
distal radius fracture
Beyond the preview
Go deeper on NCT03466242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466242.